Search Results
Jul 23, 2025, 11:09 ET BHVN INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In BHVN To Contact Him Directly To Discuss Their Options
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Faruqi & Faruqi, LLP
Jul 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia ("SCA"), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications. In May 2022, a Phase 3 trial evaluating troriluzole's
More news about: Pomerantz LLP
Jul 21, 2025, 16:02 ET BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: THE ROSEN LAW FIRM, P. A.
Jul 21, 2025, 10:04 ET BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
market. Biohaven overstated the regulatory prospects of its drug candidate troriluzole as a treatment for SCA. The Company also overstated the efficacy of BHV-7000 as a treatment for bipolar disorder. Based on these facts, the Company's public statements were false and materially misleading throughout the class
More news about: The Schall Law Firm
Jul 21, 2025, 08:45 ET Investors who lost money on Biohaven Ltd.(BHVN) should contact The Gross Law Firm about pending Class Action - BHVN
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: The Gross Law Firm
Jul 17, 2025, 16:00 ET BHVN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biohaven Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Bronstein, Gewirtz & Grossman, LLC
Jul 17, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia ("SCA"), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications. In May 2022, a Phase 3 trial evaluating troriluzole's
More news about: Pomerantz LLP
Jul 16, 2025, 19:09 ET Rosen Law Firm Urges Biohaven Ltd. (NYSE: BHVN) Stockholders to Contact the Firm for Information About Their Rights
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: THE ROSEN LAW FIRM, P. A.
Jul 16, 2025, 05:10 ET BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
market. Biohaven overstated the regulatory prospects of its drug candidate troriluzole as a treatment for SCA. The Company also overstated the efficacy of BHV-7000 as a treatment for bipolar disorder. Based on these facts, the Company's public statements were false and materially misleading throughout the class
More news about: The Schall Law Firm
Jul 16, 2025, 00:56 ET Shareholder Alert: Robbins LLP Informs Investors of the Biohaven Ltd. Corporation Class Action
is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia ("SCA"), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications.
More news about: Robbins LLP
May 29, 2025, 07:01 ET Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
of Boca Raton, Medical Director of the Parkinson's Research and Education Foundation, and Principal Investigator in the BHV8000-301 trial stated, "Biohaven is developing BHV-8000, a novel investigational highly potent, brain-penetrant, and selective dual TYK2/JAK1 inhibitor for the treatment of neuroinflammatory
More news about: Biohaven Ltd.
May 28, 2025, 15:00 ET Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)
observed with subcutaneous BHV-1400, Biohaven plans to study BHV-1400 in patients with IgAN, initiating a pivotal trial in 2026 using urine protein-creatinine ratio (UPCR) as a surrogate endpoint for accelerated approval.Optimized SC administration of BHV-1300 has continued to demonstrate
More news about: Biohaven Ltd.
May 28, 2025, 07:30 ET Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors
reduction was observed in the first 6 out of 6 patients treated with BHV-1510 plus cemiplimab including confirmed partial responsesFirst patient dosed with Biohaven's novel, first-in-class FGFR3 directed TopoIx ADC, BHV-1530Promising progress in the clinic demonstrates potential
More news about: Biohaven Ltd.
May 12, 2025, 16:05 ET Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
in 1H 2025.TRPM3 Antagonist (BHV-2100): Expect data from proof-of-concept trial with BHV-2100 in acute migraine in 1H 2025.TYK2/JAK1 Inhibitor (BHV-8000): Initiate BHV-8000 Phase 2/3 study in Parkinson's disease
More news about: Biohaven Ltd.
Apr 22, 2025, 16:32 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
loss of only $1.47 per share. The press release also disclosed that recent data from a late-stage study of the Company's BHV-7000 drug in bipolar mania "did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure". On this
More news about: Pomerantz LLP
Apr 15, 2025, 09:10 ET BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm
Company reported a larger loss than expected for the quarter. The Company also disclosed that data from its late-state clinical trial of drug candidate BHV-7000 "did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure." Based on this news, shares of Biohaven
More news about: The Schall Law Firm
Apr 14, 2025, 17:45 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
loss of only $1.47 per share. The press release also disclosed that recent data from a late-stage study of the Company's BHV-7000 drug in bipolar mania "did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure". On this
More news about: Pomerantz LLP
Apr 08, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
loss of only $1.47 per share. The press release also disclosed that recent data from a late-stage study of the Company's BHV-7000 drug in bipolar mania "did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure". On this
More news about: Pomerantz LLP
Apr 05, 2025, 09:00 ET Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting
Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and MigraineS11: PainMonday 4/7/25 11:15am-12:15pm (11:51am-12:03pm) Novel Bispecific Degrader BHV-1310 Achieves Rapid,
More news about: Biohaven Ltd.